Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 October 2019 | Story Leonie Bolleurs | Photo Leonie Bolleurs
SA animal population genetically more diverse than Europe
The Department of Genetics appointed the curator of the mammal collection in Austria’s Natural History Museum, Prof Frank Zachos. From the left are: Lerato Diseko, PhD Human Molecular Genetics; Prof Paul Grobler; Sivuyile Peni, MSc Molecular Genetics; Prof Frank Zachos; and Gerhard van Bosch, MSc Conservation Genetics.


South Africa is one of the greatest places on this planet to study mammals. These are the words of Prof Frank Zachos, newly appointed affiliated Professor in the Department of Genetics at the University of the Free State (UFS). 

He is also the curator of the Mammal Collection at the Natural History Museum in Vienna, Austria, the editor of the Elsevier journal Mammalian Biology, and author of several books, including Species Concepts in Biology. 

During a visit to South Africa, Prof Zachos addressed a group of UFS staff and students on the topic, ‘Conservation biology and genetics on two continents – case studies from mammalogy and ornithology’.

Inbreeding and deformities 

According to Prof Paul Grobler, Head of the UFS Department of Genetics, Prof Zachos has much experience in conservation biology studies. A large part of his work is on the population/conservation genetics of mammals (particularly deer) and, to a lesser degree, birds. Among others, he has studied red deer and the alpine golden eagle and has previously collaborated with Prof Grobler on projects involving local impala and gemsbok populations. 

Prof Grobler explains: “Typical conservation genetics studies helps one understand whether it's genetically going well with a species or population or not. This information can then be used to decide whether to move new animals to a population to prevent loss of genetic diversity.”

In his lecture, Prof Zachos explained the genetic diversity of red deer across Europe, and how this was influenced by past events (glaciers), but also by current anthropogenic factors (motor highways). 

He said there are several similarities between the mammals and birds of Europe and South Africa. The area south of the Sahara, however, is more of a biodiversity hotspot, unlike most areas in Europe where there is often lower genetic diversity in certain species. European deer species, for instance, are inherently less genetically diverse than antelope.

“Small population sizes can result in inbreeding. In some animals, this can result in deformities such as a shorter lower jaw or calves born without eyes,” said Prof Zachos.

Tracing geographic origin

With information on the gene diversity of a population of animals, authorities can implement preventative measures to address inbreeding, e.g. building green bridges to connect populations.

Population/conservation genetics studies are also helpful to determine which animals from a certain population are native to a specific area. Prof Zachos was involved in a study for the Belgian government, tracing the geographic and genetic origin of the country’s red deer. 

He said the ideal is to have genetic information for every population for management applications. 

During his visit, Prof Zachos also visited the Doornkloof Nature Reserve, since he is co-supervising a PhD student in the UFS Department of Genetics, who is based at Doornkloof. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept